As geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for ...
Months before the current biotech IPO boom, public investors began a more confident trek back into the sector, signaling the ...
Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a ...
Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, ...
The approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked ...
After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated ...
Belgium and the Netherlands have built some of Europe's strongest life sciences ecosystems, powered by leading research ...
BrainChild Bio’s lead asset BCB-276 is in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal brain tumor that affects around 300 children in the U.S. every year.
After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of ...
Foundation models will change the way we study the natural, applied and clinical sciences, but only under certain conditions, ...
The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution ...
Almost as many biotechs have opted for a reverse merger to reach the public markets as those executing more traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results